- All Topics
- Training & Events
- Buyer's Guide
Pall Corporation, a global leader in filtration, separation and purification, has appointed Dr. Michael Egholm as chief technology officer (CTO). Dr. Egholm assumes responsibility for directing technology research across the company’s Industrial and Life Sciences lines of business.
Eric Krasnoff, chairman and CEO of Pall Corporation, said, “I am pleased to welcome Michael as the leader of the Pall global research team. He will play a key role in our continuing mission to solve customers’ most demanding fluid management challenges and keep Pall at the forefront of innovation."
Egholm brings more than 20 years of proven leadership in developing and commercializing innovative technologies. Most recently, he served as chief technology officer and vice president of research & development at 454 Life Sciences, a center of excellence at Roche Applied Science. At Roche, he spearheaded several large high-profile programs including the Neanderthal Sequencing project and the sequencing of the first individual human genome. Previously, Egholm held senior R&D positions with Molecular Staging, where he led commercialization of genome amplification technology, and at Applied Biosystems, where he managed market development.
As a research associate at the University of Copenhagen, Dr. Egholm was the lead inventor of peptide nucleic acids (PNA) technology, a synthetic form of DNA, for which he earned his Ph.D. in organic chemistry. More than 2,300 peer-reviewed papers have been published on the properties and uses of PNA, including 42 by Egholm. He has published more than 100 papers, including several in the prestigious journals Science, Nature and The New England Journal of Medicine. An elected member of the Royal Danish Academy of Sciences and Letters, Egholm is the named inventor of 40 U.S. patents.
About Pall Corporation
Pall Corporation is a filtration, separation and purification leader providing Total Fluid Management solutions to meet the critical needs of customers in biopharmaceutical; hospital, transfusion and veterinary medicine; energy and alternative energy; electronics; municipal and industrial water; aerospace; transportation and broad industrial markets. Pall, with total revenues of $2.3 billion for fiscal 2009, is an S&P 500 company with more than 10,000 employees serving customers worldwide.